Thomas J Reid

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

B. Monk, P. Thaker, D. Silasi, 2023, International Journal of Gynecological Cancer.